281 related articles for article (PubMed ID: 34151288)
1. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia.
Gocho Y; Liu J; Hu J; Yang W; Dharia NV; Zhang J; Shi H; Du G; John A; Lin TN; Hunt J; Huang X; Ju B; Rowland L; Shi L; Maxwell D; Smart B; Crews KR; Yang W; Hagiwara K; Zhang Y; Roberts K; Wang H; Jabbour E; Stock W; Eisfelder B; Paietta E; Newman S; Roti G; Litzow M; Easton J; Zhang J; Peng J; Chi H; Pounds S; Relling MV; Inaba H; Zhu X; Kornblau S; Pui CH; Konopleva M; Teachey D; Mullighan CG; Stegmaier K; Evans WE; Yu J; Yang JJ
Nat Cancer; 2021 Mar; 2(3):284-299. PubMed ID: 34151288
[TBL] [Abstract][Full Text] [Related]
2. Preclinical evaluation of proteolytic targeting of LCK as a therapeutic approach in T cell acute lymphoblastic leukemia.
Hu J; Jarusiewicz J; Du G; Nishiguchi G; Yoshimura S; Panetta JC; Li Z; Min J; Yang L; Chepyala D; Actis M; Reyes N; Smart B; Pui CH; Teachey DT; Rankovic Z; Yang JJ
Sci Transl Med; 2022 Aug; 14(659):eabo5228. PubMed ID: 36001679
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia.
Laukkanen S; Veloso A; Yan C; Oksa L; Alpert EJ; Do D; Hyvärinen N; McCarthy K; Adhikari A; Yang Q; Iyer S; Garcia SP; Pello A; Ruokoranta T; Moisio S; Adhikari S; Yoder JA; Gallagher K; Whelton L; Allen JR; Jin AH; Loontiens S; Heinäniemi M; Kelliher M; Heckman CA; Lohi O; Langenau DM
Blood; 2022 Oct; 140(17):1891-1906. PubMed ID: 35544598
[TBL] [Abstract][Full Text] [Related]
4. Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
Saygin C; Giordano G; Shimamoto K; Eisfelder B; Thomas-Toth A; Venkataraman G; Ananthanarayanan V; Vincent TL; DuVall A; Patel AA; Chen Y; Tan F; Anthony SP; Chen Y; Shen Y; Odenike O; Teachey DT; Kee BL; LaBelle J; Stock W
Clin Cancer Res; 2023 Aug; 29(16):3151-3161. PubMed ID: 37363966
[TBL] [Abstract][Full Text] [Related]
5. Preclinical pharmacokinetic and pharmacodynamic evaluation of dasatinib and ponatinib for the treatment of T-cell acute lymphoblastic leukemia.
Yoshimura S; Panetta JC; Hu J; Li L; Gocho Y; Du G; Umezawa A; Karol SE; Pui CH; Mullighan CG; Konopleva M; Stock W; Teachey DT; Jain N; Yang JJ
Leukemia; 2023 Jun; 37(6):1194-1203. PubMed ID: 37076694
[TBL] [Abstract][Full Text] [Related]
6. Phase II-like murine trial identifies synergy between dexamethasone and dasatinib in T-cell acute lymphoblastic leukemia.
Shi Y; Beckett MC; Blair HJ; Tirtakusuma R; Nakjang S; Enshaei A; Halsey C; Vormoor J; Heidenreich O; Krippner-Heidenreich A; van Delft FW
Haematologica; 2021 Apr; 106(4):1056-1066. PubMed ID: 32139432
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid resistance is reverted by LCK inhibition in pediatric T-cell acute lymphoblastic leukemia.
Serafin V; Capuzzo G; Milani G; Minuzzo SA; Pinazza M; Bortolozzi R; Bresolin S; Porcù E; Frasson C; Indraccolo S; Basso G; Accordi B
Blood; 2017 Dec; 130(25):2750-2761. PubMed ID: 29101238
[TBL] [Abstract][Full Text] [Related]
8. Single-cell systems pharmacology identifies development-driven drug response and combination therapy in B cell acute lymphoblastic leukemia.
Huang X; Li Y; Zhang J; Yan L; Zhao H; Ding L; Bhatara S; Yang X; Yoshimura S; Yang W; Karol SE; Inaba H; Mullighan C; Litzow M; Zhu X; Zhang Y; Stock W; Jain N; Jabbour E; Kornblau SM; Konopleva M; Pui CH; Paietta E; Evans W; Yu J; Yang JJ
Cancer Cell; 2024 Apr; 42(4):552-567.e6. PubMed ID: 38593781
[TBL] [Abstract][Full Text] [Related]
9. Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia.
Kuusanmäki H; Dufva O; Vähä-Koskela M; Leppä AM; Huuhtanen J; Vänttinen I; Nygren P; Klievink J; Bouhlal J; Pölönen P; Zhang Q; Adnan-Awad S; Mancebo-Pérez C; Saad J; Miettinen J; Javarappa KK; Aakko S; Ruokoranta T; Eldfors S; Heinäniemi M; Theilgaard-Mönch K; Wartiovaara-Kautto U; Keränen M; Porkka K; Konopleva M; Wennerberg K; Kontro M; Heckman CA; Mustjoki S
Blood; 2023 Mar; 141(13):1610-1625. PubMed ID: 36508699
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia.
Harr MW; Caimi PF; McColl KS; Zhong F; Patel SN; Barr PM; Distelhorst CW
Cell Death Differ; 2010 Sep; 17(9):1381-91. PubMed ID: 20300113
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib-therapy induced sustained remission in a child with refractory TCF7-SPI1 T-cell acute lymphoblastic leukemia.
He Y; Zhang J; Zhang Y; Hu Z; Wang P; Gan W; Xie S; Qian M; Pui CH; Jiang H; Zhu X; Zhang H; Zhang W
Pediatr Blood Cancer; 2022 Aug; 69(8):e29724. PubMed ID: 35441457
[TBL] [Abstract][Full Text] [Related]
12. Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.
Cordo' V; Meijer MT; Hagelaar R; de Goeij-de Haas RR; Poort VM; Henneman AA; Piersma SR; Pham TV; Oshima K; Ferrando AA; Zaman GJR; Jimenez CR; Meijerink JPP
Nat Commun; 2022 Feb; 13(1):1048. PubMed ID: 35217681
[TBL] [Abstract][Full Text] [Related]
13. NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.
De Keersmaecker K; Porcu M; Cox L; Girardi T; Vandepoel R; de Beeck JO; Gielen O; Mentens N; Bennett KL; Hantschel O
Haematologica; 2014 Jan; 99(1):85-93. PubMed ID: 23872305
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax-Resistant T-ALL Cells Display Distinct Cancer Stem Cell Signatures and Enrichment of Cytokine Signaling.
Shah K; Al Ashiri L; Nasimian A; Ahmed M; Kazi JU
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902436
[TBL] [Abstract][Full Text] [Related]
15. Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Leonard JT; Rowley JS; Eide CA; Traer E; Hayes-Lattin B; Loriaux M; Spurgeon SE; Druker BJ; Tyner JW; Chang BH
Sci Transl Med; 2016 Aug; 8(354):354ra114. PubMed ID: 27582059
[TBL] [Abstract][Full Text] [Related]
16. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.
Chonghaile TN; Roderick JE; Glenfield C; Ryan J; Sallan SE; Silverman LB; Loh ML; Hunger SP; Wood B; DeAngelo DJ; Stone R; Harris M; Gutierrez A; Kelliher MA; Letai A
Cancer Discov; 2014 Sep; 4(9):1074-87. PubMed ID: 24994123
[TBL] [Abstract][Full Text] [Related]
17. Pre T-cell receptor alpha (pTalpha) expression patterns and functional analysis in human T-cell lymphoblastic leukemia.
Ivanyi P; Morgan M; Piao W; Ukena SN; Steube K; Ganser A; Franzke A
Cell Oncol; 2010; 32(1-2):101-8. PubMed ID: 20208138
[TBL] [Abstract][Full Text] [Related]
18. STAT5 does not drive steroid resistance in T-cell acute lymphoblastic leukemia despite the activation of
Van der Zwet JCG; Cordo' V; Buijs-Gladdines JGCAM; Hagelaar R; Smits WK; Vroegindeweij E; Graus LTM; Poort V; Nulle M; Pieters R; Meijerink JPP
Haematologica; 2023 Mar; 108(3):732-746. PubMed ID: 35734930
[TBL] [Abstract][Full Text] [Related]
19. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia.
Peirs S; Matthijssens F; Goossens S; Van de Walle I; Ruggero K; de Bock CE; Degryse S; Canté-Barrett K; Briot D; Clappier E; Lammens T; De Moerloose B; Benoit Y; Poppe B; Meijerink JP; Cools J; Soulier J; Rabbitts TH; Taghon T; Speleman F; Van Vlierberghe P
Blood; 2014 Dec; 124(25):3738-47. PubMed ID: 25301704
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion.
Zhang H; Hu Y; Shao M; Teng X; Jiang P; Wang X; Wang H; Cui J; Yu J; Liang Z; Ding L; Han Y; Wei J; Xu Y; Li X; Shan W; Shi J; Luo Y; Qian P; Huang H
J Hematol Oncol; 2021 Jul; 14(1):113. PubMed ID: 34289897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]